Bohai Pharmaceuticals has reported revenues of $59.3m for the full year ended 30 June 2010, an increase of 20%, compared to $49.3m for the comparable period in 2009.
Income from operations was $12.8m for the full year ended 30 June 2010, compared to $10m for the year ago period.
For the full year ended 30 June 2010, Bohai Pharma has posted a net income of $9.5m, or $0.57 per diluted share, compared to $7.9m, or $0.60 per diluted share, for the year ago period.
Bohai Pharma chairman, president and CEO Hongwei Qu said that they were proud of Bohai's financial results as they continue to drive revenues while simultaneously maintaining attractive margins.
Bohai Pharmaceuticals, a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditional Chinese Medicine (TCM) in China.